Table 1 AML patients’ information
From: Repositioning of bromocriptine for treatment of acute myeloid leukemia
AML sample | Gender | Age (year) | WHO subtype | WBC count (× 109/L) | % Blasts in PB | % Blasts in BM | Karyotype | Additional molecular features | ELN Risk group | FAB |
|---|---|---|---|---|---|---|---|---|---|---|
#2 | M | 28 | AML without maturation | 143 | 98 | 90 | N/A | FLT3-ITD | Intermediate | M1 |
#3 | M | 40 | AML without maturation (AML with mutated CEBPA–provisional entity-) | 52 | 66 | 80 | 46,XY | Biallelic CEBPA mutation | Favorable | M1 |
#4 | F | 34 | AML with myelodysplasia-related changes | 32 | 16 | 44 | 45,XX, -7 | FLT3wt and NPMwt | Adverse | M4 |
#5 | M | 45 | AML with t(6,9)(p23;q34); DEK-NUP214 | 40 | 58 | 43 | 46,XY,t(6;9)(p23;q34) | FLT3-ITD | Adverse | M0 |
#6 | M | 48 | AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 | 54 | 5 | 24 | 46,XY,t(8;21)(q22;q22) | FLT3N/A and NPMwt | Favorable | M2 |
#8 | M | 61 | AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 | 21.4 | 51 | 89 | FLT3wt and NPMwt | Favorable | M2 | |
#9 | F | 58 | AML with myelodysplasia-related changes | 100.7 | 45 | 80 | 46,XX, del(5)(q23q33), t(8;9)(p11;q34) [20] | FLT3wt and NPMwt | Adverse | M5 |
#10 | M | 24 | AML with myelodysplasia-related changes | 7.1 | 83 | 30 | 46,XY [20] | FLT3wt and NPMwt | Intermediate | M1 |
#11 | M | 49 | AML with myelodysplasia-related changes | 76.4 | 42 | 26 | 46-47,XY, del(5)(q22q34), del(6)(q22q25), del(7)(q22q23),-8,-9, add(11)(q23), +i(11)(q11),-16, +mar1, +mar2, +mar3[cp8]. | FLT3wt and NPMwt | Adverse | M1 |
#14 | M | 22 | AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 | 20.4 | 83 | 69 | FLT3 ITD | Favorable | M2 | |
#22 | F | 60 | AML with myelodysplasia-related changes | 218.1 | 68 | 36 | 48,XX, +8, +21 [13] | FLT3wt and NPMwt | Intermediate | M4 |